GlassScriptPhysician profile
Megan E Shirley
NPI 1447662150
$9,221.01
in general payments reported to CMS, 2019-2025
35 companies · $992 in 2025
The $992 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.98 · 2020: $790 · 2021: $1,701 · 2022: $1,731 · 2023: $2,330 · 2024: $1,657 · 2025: $992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,911 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,910.94 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,220.37 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $1,009.23 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $951.80 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $881.79 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $849.38 | 2020-2024 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $524.08 | 2019-2025 | |
| Astellas Pharma US INC | $476.53 | 2020-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $425.25 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $334.84 | 2021-2025 | Otezla, Repatha, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $321.37 | 2022-2025 | |
| Shield Therapeutics INC | $254.01 | 2023-2025 | Accrufer |
| Esperion Therapeutics, INC. | $226.49 | 2021-2025 | Nexletol |
| Daiichi Sankyo INC. | $193.80 | 2020-2023 | Injectafer |
| Janssen Pharmaceuticals, INC | $185.57 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.00 | 2020-2024 | Jardiance |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Shirley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.